Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 1(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07180355Phase 1Recruiting

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

Role: lead

NCT07148089Phase 1Recruiting

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Role: lead

NCT07160634Phase 3Recruiting

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Role: lead

NCT06138639Phase 1Recruiting

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Role: lead

NCT03368742Phase 1Active Not Recruiting

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

Role: lead

NCT05657938Completed

Evaluation of Home Based Assessments on Participants With DMD

Role: lead

NCT03680365Completed

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

Role: collaborator

All 7 trials loaded